Rize Oncology Inc.
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 643.60K | 670.90K | 621.80K | 632.50K | 582.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.22M | 1.26M | 1.22M | 984.20K | 697.00K |
| Operating Income | -1.22M | -1.26M | -1.22M | -984.20K | -697.00K |
| Income Before Tax | -1.22M | -1.25M | -1.21M | -965.40K | -672.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.22 | -1.25 | -1.21 | -0.97 | -0.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.22M | -1.25M | -1.21M | -965.40K | -672.30K |
| EBIT | -1.22M | -1.26M | -1.22M | -984.20K | -697.00K |
| EBITDA | -344.70K | -152.10K | -- | -- | -- |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 312.62M | 304.81M | 263.16M | 226.16M | 189.16M |
| Average Diluted Shares Outstanding | 312.62M | 304.81M | 263.16M | 226.16M | 189.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |